GSK logo

GSK (GSK) Stock

Profile

Full Name:

GSK plc

Sector:

Healthcare

Country:

United Kingdom

IPO:

28 March 1980

Indexes:

Not included

Description:

GSK, or GlaxoSmithKline, is a global healthcare company that focuses on pharmaceuticals, vaccines, and consumer health products. They aim to improve people's health and well-being through innovative medicines and treatments, addressing various diseases and health issues worldwide.

Key Details

Price

$36.84

TTM Dividend Yield

4.23%(+25.89% YoY)

Annual Revenue

$37.74 B(+3.92% YoY)

Annual EPS

$2.98(-67.10% YoY)

PE Ratio

23.95(+71.56% YoY)

Beta

0.24

Events Calendar

Earnings

Next earnings date:

Feb 05, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Jan 31, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Nov 15, 2024
Splits

Next split:

N/A

Recent split:

July 22, 2022

Analyst ratings

Recent major analysts updates

12 Nov '24 Jefferies
Hold
31 Oct '24 Guggenheim
Neutral
08 July '24 UBS
Neutral
02 July '24 Jefferies
Buy
30 May '24 Goldman Sachs
Neutral
04 Mar '24 Guggenheim
Buy
23 Jan '24 Morgan Stanley
Equal-Weight
03 Jan '24 Jefferies
Buy
11 Feb '22 DZ Bank
Hold
05 Nov '21 Barclays
Equal-Weight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
GSK
invezz.com05 February 2025

On Wednesday, shares of the British pharmaceutical company GSK rose significantly after it increased its long-term sales predictions and announced solid financial results for 2024. The stock jumped by 5.9% in early trading, becoming the best performer on the FTSE 100 and heading for its largest single-day increase since 2022.

GSK shares rise 5% as it navigates vaccines woes to upgrade sales target
GSK shares rise 5% as it navigates vaccines woes to upgrade sales target
GSK shares rise 5% as it navigates vaccines woes to upgrade sales target
GSK
proactiveinvestors.co.uk05 February 2025

GSK PLC (LSE:GSK, NYSE:GSK) saw its shares rise by 5% in early trading on Wednesday as the pharmaceutical company seemed to overcome concerns related to vaccines and reassured investors by increasing its long-term sales forecast. The company now anticipates that its revenue will surpass £40 billion by 2031, an increase from the previous estimate of £38 billion.

GSK upgrades long-term sales target; but Arexvy's struggles are confirmed
GSK upgrades long-term sales target; but Arexvy's struggles are confirmed
GSK upgrades long-term sales target; but Arexvy's struggles are confirmed
GSK
proactiveinvestors.co.uk05 February 2025

GSK PLC (LSE:GSK, NYSE:GSK) has increased its long-term revenue prediction, now anticipating sales to surpass £40 billion by 2031, an increase from the earlier target of £38 billion. This revision follows what the company called a "strong" financial performance in 2024, mainly due to the growth of its specialty medicines range.

GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK
reuters.com05 February 2025

GSK predicts that sales will increase by 3% to 5% in 2025 and announced fourth-quarter earnings that were better than anticipated. The strong performance in its HIV and cancer treatment areas helped balance out the decline in its vaccines sector.

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plc
Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plc
Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plc
GSK
businesswire.com04 February 2025

NEW YORK--(BUSINESS WIRE)--Today, the well-known investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) has initiated a class action lawsuit in the U.S. District Court for the Eastern District of Pennsylvania. The lawsuit claims that GSK plc (“GSK” or the “Company”) and some of its current and former executives have violated federal securities laws. This action represents all individuals or entities that bought GSK American Depositary shares.

Influenza Vaccines Market Analysis 2025-2032: GlaxoSmithKline's Influenza Vaccines Sales Declined in 2024, Driven by Competitive Pressure and Volume Phasing in the US and Lower Demand
Influenza Vaccines Market Analysis 2025-2032: GlaxoSmithKline's Influenza Vaccines Sales Declined in 2024, Driven by Competitive Pressure and Volume Phasing in the US and Lower Demand
Influenza Vaccines Market Analysis 2025-2032: GlaxoSmithKline's Influenza Vaccines Sales Declined in 2024, Driven by Competitive Pressure and Volume Phasing in the US and Lower Demand
GSK
globenewswire.com27 January 2025

Dublin, January 27, 2025 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has included a new report titled "Influenza Vaccines Market, Persons Vaccinated, By Segment - Vaccine Type, Indication, Technology, Route of Administration, End-user, Geography, Company Analysis - Global Forecast (2025 - 2032)."

GSK to explore cancer vaccines with Oxford University in £50mln deal
GSK to explore cancer vaccines with Oxford University in £50mln deal
GSK to explore cancer vaccines with Oxford University in £50mln deal
GSK
proactiveinvestors.co.uk27 January 2025

GSK PLC has announced that it will invest £50 million in research with Oxford University to develop vaccines aimed at preventing certain types of cancer. The GSK-Oxford Cancer Immuno-Prevention Programme will explore the development of pre-cancerous cells, according to the FTSE 100 pharmaceutical company.

Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
GSK
cnbc.com21 January 2025

In 2025, the biotech and pharmaceutical industries are seeing a strong beginning for dealmaking. At the same time, a report indicates that digital health fundraising in 2024 was characterized by a "David and Goliath dynamic."

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
GSK
seekingalpha.com19 January 2025

Spero Therapeutics' tebipenem, an oral carbapenem for complicated urinary tract infections (cUTIs), has a strong chance of getting approved, thanks to a successful phase 3 trial and a licensing agreement with GSK. There is a significant demand for oral carbapenems because of increasing resistance to existing oral treatments for these infections. Given its previous success in phase 3 trials and its publication in the New England Journal of Medicine, tebipenem is likely to succeed in the confirmatory phase 3 trial.

Hallucinations in AI: How GSK is addressing a critical problem in drug development
Hallucinations in AI: How GSK is addressing a critical problem in drug development
Hallucinations in AI: How GSK is addressing a critical problem in drug development
GSK
venturebeat.com14 January 2025

Hallucinations continue to be a significant issue in healthcare. GSK is addressing this by implementing test-time compute scaling to enhance its generative AI systems.

FAQ

  • What is the primary business of GSK?
  • What is the ticker symbol for GSK?
  • Does GSK pay dividends?
  • What sector is GSK in?
  • What industry is GSK in?
  • What country is GSK based in?
  • When did GSK go public?
  • Is GSK in the S&P 500?
  • Is GSK in the NASDAQ 100?
  • Is GSK in the Dow Jones?
  • When was GSK's last earnings report?
  • When does GSK report earnings?

What is the primary business of GSK?

GSK, or GlaxoSmithKline, is a global healthcare company that focuses on pharmaceuticals, vaccines, and consumer health products. They aim to improve people's health and well-being through innovative medicines and treatments, addressing various diseases and health issues worldwide.

What is the ticker symbol for GSK?

The ticker symbol for GSK is NYSE:GSK

Does GSK pay dividends?

Yes, GSK pays dividends. The last payment was $0.38, with an ex-dividend date on 15 November 2024

What sector is GSK in?

GSK is in the Healthcare sector

What industry is GSK in?

GSK is in the Drug Manufacturers - General industry

What country is GSK based in?

GSK is headquartered in United Kingdom

When did GSK go public?

GSK's initial public offering (IPO) was on 28 March 1980

Is GSK in the S&P 500?

No, GSK is not included in the S&P 500 index

Is GSK in the NASDAQ 100?

No, GSK is not included in the NASDAQ 100 index

Is GSK in the Dow Jones?

No, GSK is not included in the Dow Jones index

When was GSK's last earnings report?

GSK's most recent earnings report was on 30 October 2024

When does GSK report earnings?

The next expected earnings date for GSK is 5 February 2025